Clinical Take-Home Messages GLP-1RAs are no longer diabetes-only drugs. They are becoming: Obesity therapies Cardiovascular protective agents Anti-inflammatory therapies Neuroprotective candidates Metabolic disease modifiers Conclusion We are witnessing a historic transition in medicine
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial
Mindful eating, or taking your time while eating, may also be beneficial as well
Pratley RE, Aroda VR, Lingvay I, Ldemann J, Andreassen C, Navarria A et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Recruitment of beta arrestins desensitizes both receptors, and this is followed by internalization, recycling, and inactivation of Gas
While specific results for the combination are still an area of active research, existing preclinical data support the rationale for studying these peptides together in controlled experimental systems